retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide Dosage & Titration: Complete Escalation Protocol (5-30 mg) Retatrutide 10mg — Triple Receptor

For some people, these side effects were too rough to continue treatment

Thirty-six participants had received the investigative treatment: 23 participants had received retatrutide 4/8/12 mg (57.5 %) and 13 participants had received retatrutide 1 mg (32.5 %)

1,3 A 2025 systematic review in the International Journal of Dermatology confirmed that among GLP-1 receptor agonists, semaglutide and tirzepatide showed the highest reported incidence of hair loss, with telogen effluvium and androgenetic alopecia (AGA) identified as the predominant subtypes

Early- to mid-stage trials in people with obesity (with and without type 2 diabetes) have reported substantial average weight reductions over 48 weeks at higher doses, alongside improvements in measures like waist circumference, blood lipids and liver fat in those with metabolic fatty liver disease

[9] The Current State of Peptide Drug Discovery: Back to the Future

The dietary approach matters too